Login
$DFTX
$30.16 -$1.92 (5.99%) Live

$DFTX SEC Filings

Filed On Filing
16 Nov 2026 SCHEDULE 13G
13 Nov 2026 SCHEDULE 13G
09 Nov 2026 10-Q
09 Nov 2026 8-K: Results of Operations and Financial Condition

Definium Therapeutics Reports Third Quarter 2026 Financial Results and Recent Highlights

05 Nov 2026 SCHEDULE 13G
29 Sep 2026 Form 4: Karlin Daniel, Director

Sold 10,853 shares ($397K)

29 Sep 2026 Form 4: Barrow Robert, Director

Sold 31,550 shares ($1.15M)

29 Sep 2026 Form 4: Wiley Matthew T., Chief Commercial Officer

Sold 3,097 shares ($113K)

29 Sep 2026 Form 4: Sullivan Mark, Chief Legal Officer

Sold 14,051 shares ($514K)

29 Sep 2026 Form 4: Roberts Brandi, Chief Financial Officer

Sold 3,377 shares ($123K)

25 Sep 2026 144
25 Sep 2026 144
25 Sep 2026 144
25 Sep 2026 144
25 Sep 2026 144
18 Sep 2026 Form 4: Vallone Carol A, Director

Received 1,086 shares by exercise or conversion ($38.6K)

18 Sep 2026 Form 4: Krebs Andreas, Director

Received 1,629 shares by exercise or conversion ($57.9K)

14 Sep 2026 Form 4: Karlin Daniel, Chief Medical Officer

Received 200,000 shares as a grant or award

14 Sep 2026 Form 4: Wiley Matthew T., Chief Commercial Officer

Received 125,000 shares as a grant or award

14 Sep 2026 Form 4: Sullivan Mark, Chief Legal Officer

Received 125,000 shares as a grant or award

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support